BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27362946)

  • 21. The late recurrence of ganglioneuroma 21 years after initial presentation with neuroblastoma.
    Okita Y; Narita Y; Yoshida A; Miyakita Y; Ohno M; Saio M; Yoshimi N; Shibui S
    Pediatr Hematol Oncol; 2012 Oct; 29(7):647-51. PubMed ID: 22966943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma.
    Hoehner JC; Gestblom C; Olsen L; Påhlman S
    Br J Cancer; 1997; 75(8):1185-94. PubMed ID: 9099968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment.
    Haas D; Ablin AR; Miller C; Zoger S; Matthay KK
    Cancer; 1988 Aug; 62(4):818-25. PubMed ID: 3293764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
    Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
    Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification.
    Berthold F; Rosswog C; Christiansen H; Frühwald M; Hemstedt N; Klingebiel T; Fröhlich B; Schilling FH; Schmid I; Simon T; Hero B; Fischer M; Ernst A
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29038. PubMed ID: 33826231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic neuroblastoma with ganglioneuromatous differentiation and mandibular involvement.
    Bhattacharyya I; Williamson A; Cohen DM; Bever JL
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1999 Nov; 88(5):586-92. PubMed ID: 10556754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL; Salwen H; Quasney MW; Ikegaki N; Cowan JM; Herst CV; Kennett RH; Rosen ST; DiGiuseppe JA; Brodeur GM
    Oncogene; 1990 Dec; 5(12):1821-7. PubMed ID: 2284101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular genetic abnormalities of N-myc and C-myc in pediatric neuroblastic tumors and clinical pathologic significance].
    Cai RQ; Zhou CJ; Sun QN; Ma XL; Wang M; Li Y; Wang DY; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):299-304. PubMed ID: 24004585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MYCN oncogene and differentiation in neuroblastoma.
    Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
    Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.
    Tang XX; Evans AE; Zhao H; Cnaan A; Brodeur GM; Ikegaki N
    Med Pediatr Oncol; 2001 Jan; 36(1):80-2. PubMed ID: 11464911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathologic study of mass-screened neuroblastoma with special emphasis on untreated observed cases: a possible histologic clue to tumor regression.
    Ijiri R; Tanaka Y; Kato K; Misugi K; Nishihira H; Toyoda Y; Kigasawa H; Nishi T; Takeuchi M; Aida N; Momoi T
    Am J Surg Pathol; 2000 Jun; 24(6):807-15. PubMed ID: 10843282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
    Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
    Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
    Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.